Market Newsdesk

SAN MATEO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Cloudian® today announced that its S3 Object Lock solution is a finalist in the “Store” category for the IABM BaM Awards® 2020. Recognized as the gold standard for rewarding broadcast and media innovation, the awards honor outstanding technological offerings that deliver real business and creative benefits.

Cloudian’s object storage-based Object Lock solution protects against the rapidly growing ransomware threat by enabling media and entertainment organizations to create immutable backups of content that are then invulnerable to hacker encryption or deletion. This immutability ensures availability of an uninfected copy of the content for reliable recovery in the event of a ransomware attack, eliminating the need to pay ransom.

Unlike offline tape storage, which requires manual management and can entail significant recovery time, Object Lock can be fully automated using on-premises disk-based storage for a trouble-free, lights-out operation. In addition, Cloudian’s Object Lock solution is part of its HyperStore platform, one of only two object storage systems with Common Criteria certification, signifying that the storage is tamper-proof so immutability cannot be compromised.

“With global ransomware attacks up 40% over a year ago, and the media and entertainment industry being a key target, there is a clear need for robust data protection,” said Jon Toor, chief marketing officer at Cloudian. “Proactive approaches tend to focus on employee training and awareness, but entirely preventing human error is unrealistic, particularly with the large, distributed teams involved in modern media production. We’re honored to be recognized by IABM for providing a solution that fully safeguards content against ransomware.”

BaM Awards winners will be determined by a panel of 40 independent judges and announced on Dec. 2.

To learn more about Cloudian’s Object Lock solution and how Cloudian addresses M&E storage needs more broadly, visit http://bit.ly/RansomwareSolutions and bit.ly/CloudianMandE.

About Cloudian

Cloudian is the most widely deployed independent provider of object storage. With a native S3 API, it brings the scalability and flexibility of public cloud storage into the data center while providing ransomware protection and reducing TCO by 60% or more compared to traditional SAN/NAS and public cloud. The geo-distributed architecture enables users to manage and protect object and file data across sites—on-premises and in the cloud—from a single platform. Available as software or appliances, Cloudian supports conventional and containerized applications. More at cloudian.com.

U.S.
Media Contact

Jordan Tewell
10Fold Communications
[email protected]
415-666-6066

EMEA Media Contact

Philip Iacob
Red Lorry Yellow Lorry
[email protected]
+44 (0) 20 7403 8878

QUINCY, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) — Thanksgiving will look a lot different this year – quite literally – as a recent survey commissioned by Stop & Shop found that respondents are looking forward to wearing their coziest sweatpants, sweatshirts and slippers as opposed to dressing to the nines. The survey, which looked at Thanksgiving traditions and food preferences, also asked participants what the “silver lining” of a virtual Thanksgiving is. While one might think it’s not having to wake up at the crack of dawn to put a 20 pound bird in the oven – or only having to deal with your in-laws on Zoom (and not in-person) – 60% of respondents said they’re actually most relieved to skip out on washing the endless dishes that come with feeding a large crowd.

Stop & Shop’s Thanksgiving survey revealed the following:

• When it comes to leftovers, 63% of respondents prefer to load up their plate with round two of Thanksgiving dinner vs. a turkey, cranberry, and stuffing sandwich.
• Whether they are mashed, roasted, or scalloped, potatoes beat out stuffing as the go-to Thanksgiving side with nearly 57% of respondents saying they prefer a good spud.
• While Thanksgiving is virtual for many this year, 60% of respondents are glad not to clean up dishes after feeding a crowd.
• Another silver lining? 63% of participants are looking forward to stretchy sweatpants and slippers instead of dressing up only to go to the next room over.

“
No matter what side dish you prefer
–
or
whether
you’re celebrating in-person or virtually, it’s important we all come together to appreciate what we have this time of year
,” said
Gordon Reid, President of Stop & Shop. “
W
e’r
e
wish
ing
all of our customers
a
very
safe and happy
Thanksgiving
holiday
.”

With more than 400 locations across the Northeast plus convenient options for Delivery & Pickup, Stop & Shop can help you get ready for any kind of Thanksgiving gathering this year, whether big or small. You can also get inspired to try something new with your leftovers with recipes like Fresh Cheesy Turkey Enchiladas and Mashed Potato Cakes With Smoked Salmon for a twist on Black Friday brunch at www.stopandshop.com.

About Stop & Shop

A neighborhood grocer for more than 100 years, today’s Stop & Shop is refreshed, reenergized and inspired, delivering new conveniences for customers. Committed to helping its communities enjoy better food and better lives, Stop & Shop has a longstanding history of giving back to the neighborhoods it serves with a focus on fighting hunger and pediatric cancer care and research. The Stop & Shop Supermarket Company LLC is an Ahold Delhaize USA Company and employs nearly 60,000 associates and operates over 400 stores throughout Massachusetts, Connecticut, Rhode Island, New York and New Jersey. To learn more about Stop & Shop, visit stopandshop.com.

Media Contact:

Jennifer Brogan, [email protected]

RICHLAND, Wash., Nov. 24, 2020 (GLOBE NEWSWIRE) — The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain cancers was underscored in multiple presentations at the ASTRO 2020 annual meeting in Miami, Florida. During the virtual meeting, attendees were able to learn about the increasing body of clinical evidence showing that Cesium-131 has been found to be a valuable option in the treatment of prostate and brain cancer for clinicians and their patients.

Commenting on the presentations, Isoray CEO Lori Woods said, “It is very gratifying that so many Cesium-131 studies made it through review to the meeting proceedings of the world’s leading organization in radiation oncology. A tremendous amount of work goes into each study at these respective institutions, and each illustrates a continued interest in research related to Cesium-131 cancer treatment. We are proud that our leading brachytherapy treatment is at the forefront in bringing important benefits to cancer patients and the medical professionals who care for them.”

Two studies, The Effect of Positive Biopsy Cores on the Prognosis of Patients with Intermediate Risk Prostate Cancer Treated with Cs-131 Prostate Brachytherapy, Smith, Benoit, Beriwal, et al. UPMC, Pittsburgh PA and Report of a Large Cohort of Intermediate-Risk Prostate Cancer Patients Treated with Cs-131 Brachytherapy, Rodriguez-Lopez, Beriwal, Benoit, et al., UPMC Pittsburgh PA, looked at the use of Cesium-131, commercially known as Cesium Blu, in the treatment of intermediate risk prostate cancer. These studies make the case that many intermediate risk prostate cancer patients can be treated successfully with a Cesium-131 implant alone. Importantly, these studies show the excellent outcomes for Cesium-131 patients in this intermediate risk patient group.

Among the presentations that looked at Cesium-131 in the treatment of brain cancer was the study, A Matched Pair Analysis Of Clinical Outcomes After Intracavitary Cesium-131 Brachytherapy Versus Stereotactic Radiosurgery For Resected Brain Metastases, Vanderbilt, Schwartz, et al., Weill Cornell Medical College, NY. In this study, 30 patients with brain metastases underwent surgery and Cesium-131 brachytherapy. These patients were “matched” to 60 patients who underwent treatment of brain metastases with surgery and stereotactic radiosurgery (SRS). The patients who underwent Cesium-131 implantation at surgery as opposed to those who underwent SRS following surgery had lower rates of local recurrence and complications such as radiation necrosis.

Another study, Cs-131 Intracavitary Brachytherapy as an Adjunct to Maximal Safe Resection for Locally Recurrent High-Grade Glioma, Patel, Chen, Dusenbery, et al., Univ Minnesota, Minneapolis, involved the use of GammaTile, powered by Cesium-131 in the treatment of ten patients with brain cancers including some patients with glioblastoma multiforme (GBM). These patients had all been treated with surgery, chemotherapy, and radiation and their cancers had progressed. Nine of the ten patients had failed second line (salvage) therapy as well. The study demonstrated that treatment with Cs-131/GammaTile offers a way to provide therapeutic levels of re-irradiation that begin at the time of surgical placement of the GammaTiles. The successful delivery of high dose radiation with a low rate of complications and no radiation necrosis is very promising in the treatment of these brain malignancies.

Isoray is a medical technology company and innovator in seed brachytherapy. The Company is the world’s only producer of Cesium-131 brachytherapy, commercially known as Cesium Blu, which is powering expanding internal radiation treatment options throughout the body for difficult to treat lung, brain, gynecological, head and neck, pelvic, and colorectal cancers as well as prostate cancer.

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement

Statements in this news release about Isoray’s future expectations, including whether the studies discussed in this news release will have favorable outcomes in commercial settings, the advantages of Cesium-131 and its delivery systems coupled with surgery, the perception by patients of quality of life outcomes compared to other treatment options, whether demand for and use of Cesium-131 will increase or continue as anticipated and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether additional studies are released that support the conclusions of the studies discussed in this news release, whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results, physician acceptance, training and use of our products, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, and other risks detailed from time to time in Isoray’s reports filed with the U.S. Securities Exchange Commission. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Quanta Appoints John S. Lipman as President of North America

Alcester, Warwickshire, UK, 24 November 2020: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology company developing innovative dialysis products and services, announces the appointment of John S. Lipman as President of North America.

John will lead Quanta’s commercial operations and activities in the United States. He is already working to set up operations and to prepare for commercial launch, which is planned to follow soon after 510(k) clearance is obtained from the FDA for the company’s portable haemodialysis system SC+. He is also joined by Deborah Singer and Michelle Gazella as Head of Chronic Sales and Head of Clinical Support, respectively, bringing more than 40 years’ sales and clinical dialysis experience, with both holding senior positions at Fresenius Medical Care and NxStage.

John has over 25 years of leadership experience, developing and leading pre-launch and commercial companies across the medical device industry. John began working with Quanta as a consultant, and before that was Chief Commercial Officer at NightBalance for four years prior to its acquisition by Philips, where he was responsible for leading the US launch of the Lunoa sleep therapy device. At ApniCure John was Vice President of Marketing & Sales for eight years, where he deployed and expanded a US sales team to launch a new treatment for Obstructive Sleep Apnea. John has also held positions at FoxHollow Technologies and two Johnson & Johnson subsidiaries, LifeScan and Scios. He graduated from California Polytechnical State University and holds an MBA in Marketing from the University of San Francisco.

John E Milad, CEO of Quanta, said:
“I’m delighted that John has joined Quanta’s executive team. He brings a wealth of experience in launching novel medical products and building successful commercial organisations. I look forward to working with him to establish our US operations and bring SC+ to the world’s largest dialysis market.”

Commenting on his appointment, John Lipman said:
“I’m
excited to be leading Quanta’s US business development and commercial activity at such an important time in the company’s development. SC+ represents a unique and disruptive opportunity for the US haemodialysis market, which rarely sees any innovation. In an industry which is notoriously slow to adapt and bring benefits from new technology to patients, Quanta is offering a versatile solution, designed with flexibility and freedom in mind that could revolutionise the way we think about kidney care. I look forward to leading Quanta’s US commercial operations and working together with the senior leadership team to bring SC+ to as many patients and healthcare professionals as we can.”

-ENDS-

For more information about Quanta, please contact:

About Quanta and SC+

Based in the Midlands of the UK, Quanta is a technology-enabled provider of innovative dialysis products and services. Quanta aims to improve dialysis experiences and help people to live more freely. The lead product SC+ is a small, simple and versatile haemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments — making the therapy manageable to a broad range of users across a wide range of environments.

SC+ is commercially available in the UK, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The unobtrusive, simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

For more information, please visit our website: quantadt.com.

510(k) Pending. SC+ is not yet available for sale or use in the USA.

Jacksonville, Florida, Nov. 24, 2020 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI) (The “Company”) an emerging innovator of products, technologies and services for the rapidly growing cyber-security, digital robotics automation and A.I. for the manufacturing industry, announced today that together with Bots Marketplace, LLC, have developed a cryptocurrency trading bot that is simple and intuitive for crypto beginners to setup and run.

“The 24/7 opening hours of the crypto market has necessitated the use of trading automation for investors that are involved in trading cryptocurrencies. Understanding this, we created CryptoBOT to help investors automate, run and manage it anytime, anywhere.” – said Paul Rosenberg, CEO of BOTS, Inc.

Using familiar or popular technical indicators such as the Bollinger Band or Relative Strength Index, CryptoBot will be constantly adding more technical indicators. Besides this, CryptoBot allows you to access trade history, individual performances, profit and loss from a top-level overview to a granular level of each bot or trade. You can also select trading pairs, direction, technical indicators to enter or exit and risk management settings in the bot to trade on a connected exchange such as Binance.

For beginners, paper trade functions allow you to test bot trading using real-time data without risking actual cryptocurrencies. You’re able to backtest your strategies to get historical performances with key metrics and indicators that can help forecast future performance or shape expectations.

“We are excited about the launch of CryptoBot. CryptoBot will give many of us who are time-starved the opportunity to trade the cryptomarkets via automated trading bots. Our CryptoBot was already tested on one of the biggest Crypto Exchanges and we are ready to bring our product to other exchanges around the globe. The Company is in the final stage of negotiations to acquire an interest in one of European Crypto Exchanges, where tools like CryptoBot will be used and help traders, at the same time generating substantial revenues for BOTS, Inc.”, concluded Paul Rosenberg, CEO of BOTS, Inc.

About BOTS, Inc.

Headquartered in San Juan, Puerto Rico, BOTS, Inc., a publicly-traded OTC Markets innovator trading under the symbol (BTZI) – is a diversified company developing and servicing blockchain and robotics solutions for its clientele. The Company is committed to driving the innovations needed to shape the future of digital robotic automation management through digital technology and decentralized blockchain solutions. Management is dedicated to the strong growth of Distributed Asset Technology, Cyber Security, and Robotic Process Automation (RPA).

Shareholders, potential investors, and others should note that we announce material events and material financial information to our shareholders and the public using our website and the social media addresses listed below, as well as in our SEC filings, press releases, public conference calls, and webcasts. We also use social media to communicate with our subscribers and the public about our Company, our services, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage shareholders, the media, and others interested in our Company to review the information we post on the U.S. social media channels listed below. This list may be updated from time to time.

Track BTZI news on Facebook @ https://www.facebook.com/Bots.Bz/

Follow BTZI news on Twitter @Bots_bz http://www.Twitter.com/Bots_bz

Find BTZI news at http://www.bots.bz

Bots, Inc. has been featured in media nationwide, including CNBC, Bloomberg, TheStreet.com.

For more information, visit http://www.bots.bz

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company’s filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed in the Company’s website and filings.

Contact:

Paul Rosenberg, CEO

[email protected]